Horizon pays $3bn to bolster its pipeline
But forecasts of over $3bn in annual peak sales from Viela’s portfolio look steep.
Big pharma spinouts grow up
Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.
Go or no go? A busy month ahead for US FDA decisions
June will be hectic for the US regulator, with many approval decisions due, including one for subcutaneous Arzerra in multiple sclerosis and Tazverik in follicular…
Last-ditch rally saves 2019 float tally
A stock market rebound created a strong finish for biopharma flotations in 2019, with four $100m-plus floats, led by Phathom Pharmaceuticals.
AAN 2019 – Viela Bio takes on Alexion in neuromyelitis optica
The Astrazeneca spinout is plugging data with its rare disease contender inebilizumab, but Alexion’s Soliris is one step ahead.
Another venture funding surge sets up a strong 2018
Cell and gene therapy companies dominate the first quarter, but companies outside these fashionable areas are finding it harder to charm VCs.
